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Challenging Case
Anterior Hyaloid Fibrovascular Proliferation
Section Editor: Alireza Ramezani, MD
CASE PRESENTATION
A 64-year-old diabetic lady underwent pars 
plana vitrectomy in her left eye for a taut 
posterior hyaloid face due to proliferative 
diabetic retinopathy (PDR). Visual acuity (VA) 
at baseline had been 20/120. She had previously 
received panretinal laser photocoagulation 
(PRP) and the retinopathy had been stable, 
but there was localized extrafoveal tractional 
retinal detachment in the inferonasal quadrant. 
After vitrectomy, she was discharged in good 
condition, VA of 20/400 and mild vitreous 
hemorrhage (VH). One month postoperatively, 
the density of the VH increased and VA 
decreased to counting fingers (CF) (Fig. 1). 
The VH was non-clearing for three months 
but on echography, the retina was attached 
(Fig. 2). VH density decreased one month later 
and the patient received additional peripheral 
laser therapy. Six months postoperatively, she 
underwent uncomplicated phacoemulsification 
with intraocular lens (IOL) implantation due to 
severe lens opacity. One month after cataract 
surgery, VA was 20/400, intraocular pressure 
(IOP) was 3 mmHg and there was fibrin 
deposition over the IOL. Fundus examination 
revealed regressed PDR. She received steroid 
and cycloplegic drops and the condition 
remained stable three months after cataract 
surgery. On final examination, about 10 months 
after cataract surgery, VA deteriorated to hand 
motions, IOP was 5 mmHg, the IOL was partially 
captured by iris with fibrovasular tissue behind 
the IOL (Fig. 3); the fundus was not visible. 
The echography is shown in Figure 4.
Based on this presentation, what is your 
diagnosis, what treatment modality would you 
Figure 1.  Vitreous  hemorrhage  one  month  following 
vitrectomy.
Figure 3. IOL capture and fibrovasular tissue posterior to 
the IOL ten months after cataract surgery.
Figure 2. Non-clearing vitreous hemorrhage but attached 
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recommend and do you think there has been 
any pitfall in the management of this patient?
Bill Aylward, FRCS, FRCOphth
This appears to be a case of anterior hyaloidal 
proliferation, which is a fibrovascular response 
of the vitreous base to anterior ischemia. There 
are a number of established risk factors including 
traction as an indication for surgery, recurrent 
hemorrhage, and cataract extraction.
Although it is stated that “fundus examination 
revealed regressed PDR” at six months, it is 
quite likely that the anterior retina remained 
very ischemic and continued to produce large 
quantities of vascular endothelial growth factor 
(VEGF) which diffused forward, aided by the state 
of pseudophakia. The low IOP is due to traction 
on the ciliary body. This is a very serious situation, 
and in retrospect might have been avoided by 
more aggressive trimming of the vitreous base 
at the time of initial surgery together with heavy 
peripheral panretinal photocoagulation.
If the patient is keen on further treatment 
now (and without it the eye is lost), I would 
recommend intravitreal injection of an anti-
VEGF followed by further surgery 6 days later. 
This surgery should remove as much of the 
anterior fibrous tissue as possible, and apply 
additional PRP as far forward as possible. The 
surgeon will find a dense white band of fibrous 
tissue over the ciliary body, and I recommend 
that they resist the temptation to peel this off! 
Finally I recommend silicone oil tamponade, as 
this will help counter the hypotony, as well as 
acting as a ‘VEGF insulator’ to guard against 
furthers proliferation.
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Ramin Tadayoni, MD
Based on the provided information, this 
lady’s left eye presents a diabetic anterior 
fibrovascular proliferation (Fig. 3) associated 
with severe tractional retinal detachment 
(Fig. 4).  IOP is low and the eye seems already 
on the way to phthisis bulbi. At this stage 
and despite all heroic interventions, the 
prognosis remains very poor. A vitrectomy 
with dissection of proliferations and probably 
anterior retinectomy, IOL removal and silicone 
injection could be a last chance treatment.
These conditions could sometimes be 
prevented by early diagnosis and intervention: 
generous photocoagulation of all anterior 
ischemic areas, treatment of significant retinal 
detachment in particular in the anterior retina 
and intraocular use of anti-VEGF agents. 
This complication must be in mind when 
hypotony, especially associated with a vitreous 
hemorrhage, is diagnosed after any surgery for 
diabetic retinopathy.
Further upstream, the risk of these 
complications usually justifies a reoperation 
if the fundus remains inaccessible for more 
than one month after vitrectomy for diabetic 
retinopathy due to vitreous hemorrhage, to 
check the retina and treat the cause of bleeding. 
In high-risk cases (in particular cases with 
proliferation extending forward to the equator), 
some surgeons systematically inject anti-VEGF 
agents at the end of the vitrectomy, even though 
its benefit has not been clearly proven.
Figure 4. Posterior segment appearance 10 months after 
cataract surgery.Challenging Case; Anterior Hyaloid Fibrovascular Proliferation
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Fernando Arevalo, MD
This is a 64-year-old woman with diabetes 
mellitus and history of decreased vision in the 
left eye, pars plana vitrectomy and PRP for 
management of PDR. Later on she underwent 
phacoemulsification with IOL implantation. 
Sixteen months after initial evaluation, VA 
was CF and IOP was 5 mmHg. Examination 
revealed that the IOL was partially captured, 
there was fibrovasular tissue behind the IOL, 
and the fundus was not visible. Echography 
demonstrated vitreous hemorrhage, tractional 
retinal detachment (TRD) with proliferation 
and a posterior closed funnel. The choroid 
is thickened, and the axial length of the eye 
seems decreased as compared to previous 
echographic images. It is clear that this is a 
case of a TRD, fibrinoid syndrome and a pre-
phthisical eye following vitrectomy, PRP, and 
phacoemulsification with IOL implantation for 
management of severe PDR.
At this point, I would consider surgery if 
this is the only eye. My approach would be to 
perform a 23-gauge transconjunctival sutureless 
vitrectomy with membrane peeling, IOL removal 
and silicone oil (SO) injection. My preference 
on a complicated case like this would be to use 
5,000 centistoke (cs) SO. We have previously 
reported a higher rate of complications using 
1,000 cs SO for complex retinal detachment repair 
including retinal redetachments, reproliferation, 
glaucoma, hypotony, keratopathy, cataract; 
furthermore, SO emulsification tends to occur not 
only more frequently but also faster with 1000 
cs SO. Effective management for postoperative 
hypotony is problematic, revision of vitrectomy 
with peeling of membranes from the ciliary 
processes might be of value. In addition, 
subconjunctival injections of long-acting (depot) 
steroids may be given (anterior subconjunctival 
injections as opposed to posterior sub-Tenon 
injections are more likely to produce an 
elevation/normalization of IOP). No intravitreal 
bevacizumab should be used at this stage as it 
could induce worsening of the TRD.
In retrospect, I would have treated the 
vitreous hemorrhage earlier with a fluid-air/
gas exchange to avoid fibrin development. 
In addition, I would have treated the fibrin 
deposition over the IOL with intracameral tissue 
plasminogen activator at a dose of 25 μg/0.1 
mL. Any fibrin appearing in the frontal plane 
as a result of severe inflammation may result 
in development of a cyclitic membrane and 
phthisis bulbi in severe cases. Steroids do not 
appear to retard healing of any of the ocular 
structures and should be adequately used to 
suppress all inflammation.
In summary, this is a 64-year-old woman 
with diabetes mellitus and history of decreased 
vision in the left eye, pars plana vitrectomy 
and PRP for PDR, and phacoemulsification 
with IOL implantation. She developed a TRD, 
fibrinoid syndrome and a pre-phthisical eye 
with hypotony. Surgery is warranted if this is 
an only eye but the patient should be warned 
that the prognosis is poor.
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Reza Karkhaneh, MD
This is a case of vitreous hemorrhage after 
vitrectomy for PDR, a common complication 
with  an  incidence  of  12%  to  63%.  The 
hemorrhage may appear within the first few 
weeks after surgery or months later. The source 
of early bleeding in such cases may be residual 
blood in the peripheral vitreous skirt, iatrogenic 
intraoperative injury to retinal vessels, and 
incomplete removal of fibrovascular tissues. Challenging Case; Anterior Hyaloid Fibrovascular Proliferation
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The cause of late vitreous hemorrhage (one 
month postoperatively in this patient) can be 
fibrovascular proliferation from the sclerotomy 
sites or from the vitreous base. The vitreous 
hemorrhage persisted for three months after 
vitrectomy, during this period the retina was 
attached as revealed by B scan ultrasonography.
In this case it may be difficult to differentiate 
the origin of vitreous hemorrhage by conventional 
methods of examination using an indirect 
ophthalmoscope or B scan ultrasonography 
because of poor visibility and limited scope of 
evaluation of anterior segment structures to 
detect complications at the sclerotomy sites. On 
the other end, ultrasound biomicroscopy (UBM) 
is helpful to provides images of fibrovascular 
ingrowth at sclerotomy sites. Postvitrectomy 
vitreous hemorrhage clears more rapidly in 
aphakic eyes (at an average of 5.3 weeks) than 
in phakic eyes (at an average of 16.2 weeks).
Vitreous hemorrhage decreased four 
months after surgery in this case and the patient 
received additional peripheral laser therapy. Six 
months after vitrectomy the patient underwent 
uncomplicated phacoemulsification with IOL 
implantation. An important finding was ocular 
hypotonia one month after cataract surgery 
which may have been due to peripheral retinal 
detachment or anterior retinal displacement 
and ciliary body detachment secondary to 
fibrovascular proliferation from the sclerotomy 
sites or from the vitreous base. At this stage of the 
disease, UBM imaging is highly recommended. 
UBM also is helpful for early diagnosis and 
timely management of such complications.
Presence of any fibrovascular proliferation 
at the sclerotomy site would indicate the need 
for more aggressive retinal ablation, especially 
to the periphery, with the indirect laser 
delivery system, transconjunctival cryopexy, 
or transconjunctival diopexy with diode laser. 
It appears that these complications could have 
been diagnosed and treated earlier.
Finally about 10 months after cataract 
surgery there was massive fibrovasular tissue 
behind the IOL and IOP was 5 mmHg, the B-scan   
ultrasonography showed advanced TRD of the 
posterior and peripheral retina. These findings are 
consistent with anterior hyaloidal fibrovascular 
proliferation. It is a severe complication after 
vitrectomy for PDR, which, if not treated 
aggressively can lead to phthisis bulbi. Therefore 
despite the poor prognosis and visual outcome 
in this case, it is recommended to perform 
vitrectomy, remove all fibrovascular proliferation 
at the sclerotomy sites and peripheral retina, 
repair the retinal detachment, aggressively 
perform retinal ablation especially to the 
periphery of the retina with endolaser, indirect 
laser delivery system, cryopexy, or diopexy, 
and inject silicone oil. I would prefer to inject 
intravitreal bevacizumab and triamcinolone 
acetonide at the conclusion of surgery in this case.
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